import MCQGroup from '@/components/MCQGroup'
import { Callout } from 'nextra/components'

# Diabetic Maculopathy

Diabetic maculopathy (also known as diabetic macular oedema) is a significant complication of diabetic retinopathy that can lead to loss of central vision if not treated promptly.

## Diagnosis

Diabetic maculopathy may be associated with both non-proliferative and proliferative diabetic retinopathy. It encompasses the following classifications, which can be diagnosed from slit-lamp examination:

- **Focal:** Discrete areas of leakage – oedema and exudates – surrounding microaneurysms.
- **Diffuse:** Generalized leakage characterized by widespread retinal swelling.
- **Ischaemic:** Reduced visual acuity despite normal examination findings; macular ischaemia is detectable on further investigations.
- **Clinically significant macular oedema:** Thickening and/or presence of hard exudates in the macula.

## Investigations

To confirm the diagnosis, the following investigations are utilized:

- **Fundus fluorescein angiography**
- **Optical coherence tomography (OCT)**

## Management

Management is analogous to that of diabetic retinopathy. Prevention of diabetic maculopathy can be achieved by controlling systemic risk factors (glycaemic, lipid, and hypertensive) and conducting annual screenings for diabetic retinopathy and maculopathy in patients with diabetes.

### Treatment for Clinically Significant Macular Oedema

Patients diagnosed with clinically significant macular oedema should receive treatment through one or more of the following modalities:

- **Intravitreal VEGF inhibitors:** 
  - e.g., ranibizumab, aflibercept (1st line).
  - **Complications:** Endophthalmitis, vitreous haemorrhage, and retinal tears/detachment.

- **Laser Photocoagulation:**
  - **Complications:** Subretinal fibrosis, extension of the scars into the fovea, and scotoma.

- **Combined Therapy:** 
  - A combination of laser treatment and intravitreal VEGF or corticosteroid therapy.

<Callout emoji="⚠️">
**Warning:** Patients should be monitored for potential complications following any treatment modality.
</Callout>

<details>
<summary>Common Signs and Symptoms</summary>

- **Vision Symptoms**
  - Blurred or distorted vision
  - Difficulty seeing colours
  - Dark or empty areas in central vision

- **Ocular Discomfort**
  - Eye pain or discomfort
  - Changes in perception of light

- **Other Symptoms**
  - May be asymptomatic in early stages
</details>

## References

[Diabetic Macular Edema - EyeWiki](https://eyewiki.aao.org/Diabetic_Macular_Edema)

---

<MCQGroup questions={[
  {
    question: "A 55-year-old man with poorly controlled type 2 diabetes mellitus presents with progressively worsening visual acuity. Fundus examination reveals the presence of hard exudates and retinal edema. What is the most appropriate initial management for this patient?",
    options: [
      "Annual monitoring without treatment",
      "Intravitreal VEGF inhibitors",
      "Laser photocoagulation",
      "Intravitreal corticosteroids",
      "Correction of systemic risk factors"
    ],
    correctAnswer: 5,
    correctFeedback: "Correct! The initial management should focus on controlling systemic risk factors, including glycemic control, lipid management, and hypertension. This is crucial to prevent further progression of diabetic maculopathy. Once the risk factors are optimized, treatment options can be considered depending on the severity of the maculopathy.",
    incorrectFeedback: "Think about the importance of systemic management in diabetic conditions. Before considering invasive procedures or pharmacotherapy, it is vital to stabilize blood glucose and other systemic parameters. Which management strategies addressed systemic risk factors could help prevent progression?"
  },
  {
    question: "During a follow-up visit, the same patient develops clinically significant macular edema. After optimizing systemic control, which treatment option is considered first-line for managing clinically significant macular edema?",
    options: [
      "Laser photocoagulation",
      "Intravitreal corticosteroids",
      "Intravitreal VEGF inhibitors",
      "Observation without treatment",
      "Oral corticosteroids"
    ],
    correctAnswer: 3,
    correctFeedback: "Correct! Intravitreal VEGF inhibitors such as ranibizumab and aflibercept are the first-line treatments for clinically significant macular edema. They help reduce retinal edema and improve visual outcomes. Other options are either less effective or not first-line.",
    incorrectFeedback: "Consider the class of medications that directly target the underlying pathophysiology of macular edema in diabetic patients. Which treatments are specifically indicated for this condition and have the best evidence supporting their use in the context of managing edema?"
  },
  {
    question: "A patient with diabetic maculopathy undergoes intravitreal injection of aflibercept. What is a potential complication of this treatment that requires careful monitoring?",
    options: [
      "Increased intraocular pressure",
      "Endophthalmitis",
      "Retinal detachment",
      "Subretinal hemorrhage",
      "Cataracts"
    ],
    correctAnswer: 2,
    correctFeedback: "Correct! Endophthalmitis is a serious but rare complication of intravitreal injections, which underscores the necessity for strict aseptic technique during the procedure and careful post-injection monitoring of the patient. Awareness of this risk is essential for timely management.",
    incorrectFeedback: "Reflect on the risks associated with invasive ocular procedures. Complications can occur due to the nature of the procedure itself. Which serious complications are documented specifically with intravitreal injections, and how might clinical vigilance help mitigate these risks?"
  },
  {
    question: "A patient with known diabetic retinopathy comments on experiencing blurred vision and difficulty in seeing colors. Based on these symptoms, which type of diabetic maculopathy might this patient be experiencing?",
    options: [
      "Ischaemic maculopathy",
      "Focal diabetic macular edema",
      "Diffuse diabetic macular edema",
      "Clinically significant macular edema",
      "All of the above"
    ],
    correctAnswer: 4,
    correctFeedback: "Correct! These symptoms are indicative of clinically significant macular edema, as they reflect reduced visual acuity and distortion, which can occur due to retinal swelling. Prompt assessment and management are essential to prevent vision loss.",
    incorrectFeedback: "Consider how different manifestations of diabetic maculopathy may present with similar symptoms. Focus on the nature of the visual complaints: blurred or distorted vision and color perception changes are hallmark features that suggest significant abnormalities in the macula's functionality. Which forms of diabetic maculopathy are most likely to lead to these experiences?"
  }
]} />